诺和诺德

  	      	      	    	    	      	    
 
 
 
  
 本条目包含过多不是中文的内容，欢迎协助翻译。
 
若已有相当内容译为中文，可迳自去除本模板。 
 
诺和诺德（Novo Nordisk）:世界领先的糖尿病治疗公司 
诺和诺德英文官方网站：http://www.novonordisk.com  
诺和诺德中文官方网站：http://www.novonordisk.com.cn  
 
目录
 
 
1 诺和诺德简介
 
2 Novo Nordisk
 
3 Company Logo
 
4 Unite for Diabetes
 
5 Timeline
 
 
 
诺和诺德简介
 
　　诺和诺德（Novo Nordisk，OMX: NOVO B, NYSE: NVO）是世界领先的生物制药公司，在用于糖尿病治疗的胰岛素开发和生产方面居世界领先地位。诺和诺德总部位于丹麦首都哥本哈根，员工总数18,000人，分布于70个国家，产品销售遍布179个国家。在欧美均建有生产厂。 
    诺和诺德的历史最早可追溯至1923年。近80年来，诺和诺德不断运用先进的生物技术完善胰岛素研究和生产手段，取得突破性进展，成为这一领域的先驱。诺和诺德率先推出长效胰岛素，预混胰岛素，高纯胰岛素，人体胰岛素和胰岛素注射笔。同时，诺和诺德又率先推出新一类的口服降糖药-诺和龙，从而极大地提高了糖尿病治疗和控制水平，改善了糖尿病人的生活质量。此外，诺和诺德还在凝血治疗、生长保健以及激素替代疗法等很多方面居世界领先地位。 
    诺和诺德的产品60年代初就已进入中国市场。1994年初，诺和诺德董事会通过了在中国实施战略投资的计划，在北京建立诺和诺德（中国）制药有限公司总部和生物技术研究发展中心，并在天津兴建现代化生产工厂。 
    诺和诺德的标志是古埃及动物Apis公牛，它被看成是掌管科学和艺术之神-Ptah的化身，象征着生命和健康。公司标志是1925年根据一尊公元前600 年的古埃及青铜雕像设计的。诺和诺德公司选用Apis公牛作为标志，象征着公司继承和发扬几百年来药学家和化学家努力进取，不断探索的古老传统。 
    主要产品：人胰岛素系列－诺和灵 诺和针 诺和英 诺和笔；新一代速效胰岛素注射液 诺和锐；促胰岛素分泌剂 诺和龙；人胰高血糖素诺和生 
 
Novo Nordisk
 
Novo Nordisk (Template:OMX, NVO) manufactures and markets pharmaceutical products and services. Created in 1989 through a merger of two Danish companies dating back to the 1920s, it has become one of the world's leading companies in diabetes care, where Novo Nordisk pursues research into pulmonary delivery systems; other companies, such as Meditronic, have expanded into insulin pump systems. Novo Nordisk also commands large sectors of the markets in haemostasis management, growth hormone therapy and hormone replacement therapy. 
With headquarters in Denmark, Novo Nordisk has production facilities in six countries, with affiliates or offices in 80 countries. Novo Nordisk employs approximately 26,000 people globally (as of 2007)[1] , and markets its products in 179 countries. 
Novo Nordisk founded the World Diabetes foundation to save the lives of those affected by diabetes in developing countries and were instrumental in achieving a UN resolution to fight diabetes. Making diabetes the only other disease alongside HIV / AIDS to have a commintment to combat at a UN level. 
 
Company Logo
 
The Novo Nordisk logo is the Apis bull, one of the sacred animals of ancient Egypt. The Apis bull was worshipped as the incarnation of Ptah, creator of the universe, city god of Memphis and the patron deity of craftsmen. 
The logo is a stylised reproduction of an Egyptian statuette dating from circa 664–323 BC. It is richly ornamented with symbols representing, among other things, the eternal dualities of life, day and night, life and death. 
The Apis bull has been Novo’s logo since the year after the company’s foundation. The choice of the logo follows an old European chemist's tradition of identifying pharmacies by an animal symbol. 
 
Unite for Diabetes
 
Novo Nordisk have sponsored the International Diabetes Federation's Unite for Diabetes campaign — a campaign that has successfully achieved a UN Resolution on Diabetes. 
As such, they have also launched the Novo Nordisk Changing Diabetes World Tour — a truck that folds out into an educational and awareness-developing bus. The vehicle was launched in Copenhagen in September 2005 and has visited Europe, Africa, Australia, Asia, the Indian subcontinent and the United States. The bus journey culminated in being stationed in New York City for the inaugural World Diabetes Day on November 14, 2007. 
 
Timeline
 
Template:References Novo Nordisk was created in 1989 through a merger between two Danish companies – Novo Industri A/S and Nordisk Gentofte A/S. 
 
 1923 Nordisk Insulinlaboratorium (later Nordisk Gentofte) founded. 
 1925 Novo Terapeutisk Laboratorium (later Novo Industri) founded. 
 1932 Nordisk Insulinlaboratorium founds the Steno Memorial Hospital. 
 1938 Novo founds Hvidøre Diabetes Sanatorium. 
 1941 Novo launches its first enzyme, trypsin, extracted from the pancreas of animals and used for bating leather before tanning. 
 1946 Nordisk develops isophane insulin, branded as Neutral Protamine Haegdorn or NPH insulin, a neutral insulin with prolonged action. 
 1947 Penicillin Novo is launched – Novo's first product to be manufactured through fermentation. 
 1953 Lente – a long-acting insulin zinc suspension – is launched. 
 1963 Alcalase – Novo's first detergent enzyme produced by fermentation. 
 1973 Nordisk Gentofte markets Nanormon growth hormone for the treatment of growth hormone insufficiency. The growth hormone is extracted from human pituitary glands. 
 1973 Monocomponent (MC) insulin is introduced – the purest insulin available. 
 1974 Novo's B shares are quoted on the Copenhagen Stock Exchange. 
 1977 Trisequens – sequential combined oral hormone replacement therapy (HRT) for peri-menopausal women – is marketed. 
 1977 Novo enters the U.S. insulin market, but based on market share data, the company was a very marginal player. 
 1978 In an effort to alleviate its product and quality problems in the U.S. insulin market, E.R. Squibb & Sons contracts with Novo. Novo becomes the single bulk supplier of insulin for Squibb. 
 1981 Novo becomes the first company in Scandinavia to be quoted on the New York Stock Exchange. 
 1982 Novo enters into a 50/50 U.S. joint venture with E.R. Squibb & Sons, known as Squibb-Novo, based in Princeton, NJ. Squibb-Novo became the distributor for Novo insulin sold in the U.S. market, with Novo focused on producing insulin, and Squibb focused on distributing and selling the product. The joint venture is able to significantly increase Novo's U.S. market share. 
 1982 'Human' Monocomponent insulin is launched in the U.S. – the world's first insulin preparation which is structurally identical to human insulin. It is extracted from the pancreas of pigs and converted to human insulin chemically. 
 1983 Novo Industri A/S enters a joint venture with Canada's Connaught Laboratories, considered to be the birthplace of insulin. Under the terms of the agreement, Novo agreed to manufacture insulin in Canada for distribution by Connaught. Novo Laboratories Ltd. agreed to lease, modernize and operate Connaught's insulin production facilities. Another subsidiary company, Connaught-Novo, was jointly owned by both parent companies. Connought Laboratories was privatized by the Mulroney government in 1985. 
 1985 NovoPen – an injection system similar in appearance to a fountain pen, with replaceable insulin cartridges – is launched. 
 1987 Novo starts production of human insulin with the help of genetically engineered yeast cells using recombinant DNA technology. 
 1988 Nordisk Gentofte markets Norditropin genetically engineered human growth hormone. 
 1989 Novo Industri A/S and Nordisk Gentofte A/S merge to become Novo Nordisk A/S, the world's leading producer of insulin. 
 1989 Following the merger of Novo and Nordisk, and the merger of Bristol-Myers and E.R. Squibb & Sons, the Squibb-Novo joint venture in the U.S. was dissolved. Novo purchased Squibb's 50% share and all rights to the joint U.S. diabetes care business. 
 1989 NovoLet – the world's first prefilled insulin syringe – is marketed. 
 1992 The Steno Memorial Hospital and Hvidøre Hospital merge to form the Steno Diabetes Center. 
 1994 Novo Nordisk Canada Inc. and Connaught Laboratories Ltd. announced a distribution agreement, which replaced their joint venture which was known as Connaught Novo Nordisk Inc. Under the terms of the agreement, Connaught received a financial consideration and a percentage fee for distribution services related to Novo Nordisk Canada's diabetes care products. Connaught continued to distribute Novo Nordisk Canada's diabetes products in Canada and Bermuda. 
 1994 Novo Nordisk is the first company in Denmark – and one of the first in the world – to publish an environmental report. 
 1996 NovoSeven – for the treatment of haemophilia patients with inhibitor reaction – is launched. 
 1998 NovoNorm/Prandin, a new oral treatment for type 2 diabetes, is launched in the US and a number of European countries. 
 1998 Activelle – the first low-dose continuous combined oral HRT for post-menopausal women – is introduced. 
 1999 Novo Nordisk publishes its first social report. 
 1999 Innovo, the world’s first insulin doser with a built-in electronic memory, is launched in Europe. 
 1999 NovoRapid (NovoLog in the US) – a rapid-acting insulin analogue – is marketed. 
 1999 Norditropin SimpleXx – the world’s first liquid growth hormone in a dedicated pen system – is launched. 
 2000 Novofem, a low-dose sequential combined oral HRT, is marketed in Germany. Two years later it is launched in several other European countries. 
 2000 Novo Nordisk is split into three separate companies operating under the umbrella of the Novo Group: Novo Nordisk A/S, Novozymes A/S and Novo A/S. 
 2001 InnoLet – the first insulin delivery system specially designed to suit the needs of insulin users with poor eyesight and reduced dexterity – is launched. 
 2001 InDuo – the world’s first combined blood glucose monitor and insulin injection system – is introduced. 
 2001 NovoRapid FlexPen and Insulatard (NPH) FlexPen are marketed. FlexPen is a new prefilled pen, designed to be easy and discreet to use. 
 2001 Novo Nordisk acquires the controlling interest in the Brazilian pharmaceutical company Biobrás. 
 2002 NovoMix 30 FlexPen and NovoMix Penfill are introduced. NovoMix 30 is a dual-release insulin analogue. 
 2004 Levemir – a long-acting insulin analogue – is launched. 
 2005 Novo Nordisk announced that the company had moved into a leadership position in the U.S. insulin market for the first time ever based on the most recent data on total insulin volume.[2]